Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

Jee Hung Kim; Su-Jin Shin; Soo Jin Heo; Eun-Ah Choe; Chang Gon Kim; Minkyu Jung; Ki Chang Keum; Jin Sook Yoon; Sung Chul Lee; Sang Joon Shin

doi:10.4143/crt.2017.534

Articles

Page Path: HOME > Cancer Res Treat > Volume 50(4); 2018 > Article

Original Article Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma: Jee Hung Kim, MD^1,2, Su-Jin Shin, MD, PhD³, Soo Jin Heo, MD¹, Eun-Ah Choe, MD, PhD¹, Chang Gon Kim, MD^1,4, Minkyu Jung, MD, PhD¹, Ki Chang Keum, MD, PhD⁵, Jin Sook Yoon, MD, PhD⁶, Sung Chul Lee, MD, PhD⁶, Sang Joon Shin, MD, PhD^1,; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2018;50(4):1238-1251.
DOI: https://doi.org/10.4143/crt.2017.534
Published online: December 28, 2017

¹Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

²College of Medicine, Yonsei University Graduate School, Seoul, Korea

³Department of Pathology, Hanyang University College of Medicine, Seoul, Korea

⁴Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea

⁵Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea

⁶Institute of Vision Research, Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea

Correspondence: Sang Joon Shin, MD, PhD Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-4320 Fax: 82-2-393-3652 E-mail: SSJ338@yuhs.ac

• Received: November 8, 2017 • Accepted: December 27, 2017

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

11,839 Views
233 Download
15 Web of Science
14 Crossref
16 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood of recurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression-free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy.
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)‒negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival.
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.
Key words: Uveal neoplasm, Melanoma, Recurrence, Survival, Prognosis, BAP1

Introduction

Uveal melanoma, the most common primary intraocular cancer, has a very poor prognosis, with reported median overall survival durations of 4-15 months [1-3]. Uveal melanoma is usually asymptomatic and is often diagnosed incidentally during routine ophthalmic examinations. Accordingly, appropriate treatment is often delayed. Although primary uveal melanomas are often successfully eradicated, nearly 50% of patients develop systemic metastatic disease [2], which almost always involves the liver (89%) [3]. Metastases of uveal melanoma are rarely detectable at the time of the first local ocular treatment, and recent studies have shown that patients undergo routine liver ultrasonography screening to detect metastatic sites [4]. However, no standard screening protocol for uveal metastases currently exists, and ultrasonography alone often fails to detect hepatic sites.

Chemotherapeutic agents such as dacarbazine or gemcitabine/treosulfan are often administered to patients in whom recurrent uveal melanoma has been detected, although limited evidence supports the use of these regimens. Specifically, these patients rarely exhibit clinical responses, and therefore the efficacy of systemic chemotherapy is questionable [1]. Currently, the immunotherapeutic agents nivolumab and pembrolizumab, which are fully human monoclonal antibodies specific for the programmed cell death protein 1 (PD-1) receptor, have been approved in the United States for the treatment of advanced melanoma. However, PD-1 inhibitors have not been demonstrated to improve the survival of patients with uveal melanoma, and previous studies reported a median progression-free survival (PFS) and overall response rate of only 3 months and 3.6%, respectively [5,6].

Several groups have studied the prognostic factors of uveal melanoma. For example, Harbour et al. [7] reported an inactivating somatic mutation of BAP1, the gene encoding BRCA-associated protein 1 (BAP1), in predominantly metastatic uveal melanomas. This mutation was later found to correlate strongly with the risk of metastasis [8]. Another study demonstrated associations of ciliary body involvement, the largest tumor diameter, and extraocular extension with a significantly poor prognosis in patients with uveal melanoma [9].

In the present retrospective study, we identified prognostic predictors of distant recurrence and survival after recurrence in 226 patients with uveal melanoma who received primary local therapy at our hospital between 1990 and 2015. We aimed to study the time interval between the diagnoses of primary and recurrent uveal melanoma and the efficacies of systemic therapies after recurrence. We also delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.

Materials and Methods

1. Patients and data collection

We retrospectively reviewed the medical records of 226 patients who were diagnosed with stage I-III uveal melanoma between January 1990 and December 2015 at the Department of Ophthalmology, Yonsei University College of Medicine and the Yonsei Cancer Center. The inclusion criteria were as follows: (1) a diagnosis of uveal melanoma, (2) treatment with local resection or radiotherapy at the time of diagnosis, (3) no distant metastases at the time of diagnosis, and (4) available clinical data at the time of treatment.

We collected baseline clinical variables, including age, sex, and co-morbidities, and tumor data, including location, size, initial stage, and histology. Histologic classification of the primary uveal melanoma was performed through the enucleation report, local excision or ciliary body excision. The largest basal diameter (LBD) and depth of each tumor were measured using B-scan ultrasonography (Ellex, Adelaide, SA, Australia). Tumor staging was based principally on the Guideline for Uveal Melanoma from the American Joint Committee on Cancer (AJCC) Cancer Staging Manual, seventh edition [10].

2. Treatment

Local radiotherapy was performed as described in previous studies [11,12]. Brachytherapy with ¹⁰⁶Ru plaques (Eckert & Ziegler BEBIG, Berlin, Germany) was primarily performed as an eye-sparing treatment. The range of target radiation doses to the tumor apex was 85-100 Gy. Some patients also received adjuvant trans-pupillary thermotherapy (TTT) using a diode laser with a slit-lamp delivery system at 3-month intervals, based on therapeutic responses. The exposure duration was 1 minute per spot, and the laser power was adjusted until the tumor surface became grayto-white within 1 minute.

Primary enucleation was performed for large tumors. Patients who strongly refused enucleation underwent brachytherapy. A surgical biopsy was performed when histologic confirmation was required. External sclerouvectomy was generally performed for ciliary body melanoma and anterior choroidal melanoma; endoresection via trans pars plana vitrectomy (TPPV) was performed for posterior choroidal melanoma [13-15].

Forty-nine patients who developed distant recurrences following initial local treatment underwent metastasectomy and/or palliative first-line systemic treatments comprising chemotherapies and immunotherapies.

3. Immunohistochemistry

Tumor immunohistochemistry (IHC) was performed using a Ventana XT automated staining system (Ventana Medical Systems, Tucson, AZ) according to the manufacturer’s protocol in the 69 primary and 20 metastatic uveal melanoma tissues. Four-micron-thick sections were immunostained with primary antibodies specific for BAP1 (1:50, C-4, mouse monoclonal, Santa Cruz Biotechnology, Dallas, TX), which yielded a nuclear staining pattern. BAP1 expression was determined according to the percentage of BAP1-positive cells among all melanoma cells. Samples with a BAP1-positive cell frequency of < 5% were considered to have lost BAP1 expression.

4. Statistical analysis

For the analysis, datasets were classified as “before” or “after” distant recurrence. Before recurrence, we reviewed the primary tumor characteristics and local treatment efficacies. Recurrence-free survival (RFS) was defined as the time from the initial diagnosis of uveal melanoma to the time of distant recurrence. After recurrence, we reviewed medical records concerning recurrence patterns and the efficacies of systemic palliative treatment and surgery. The disease control rate (DCR) was defined as the proportion of patients who achieved a complete response, confirmed partial response, or stable disease per the Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1. PFS was defined as the time interval from the initiation of first-line systemic therapies to the date of documented disease progression or death from any cause. OS1 was measured from the date of initial diagnosis with uveal melanoma to the date of death from any cause, and OS2 was measured from the date of distant recurrence to the date of death from any cause.

The primary endpoint of the study, OS2, was calculated using the Kaplan-Meier product-limit method, and survival rates were compared statistically using the log-rank test and generalized Wilcoxon test. All univariate analyses included the following factors: age, sex, histology, size, tumor stage and location, distant metastasis pattern, and treatment modality. The multivariate analysis was performed using stepwise Cox proportional hazards regression modeling. p-values of < 0.05 were considered statistically significant, and all p-values corresponded to two-sided significance tests. Data were analyzed using SPSS software ver. 23.0 (IBM Corp., Armonk, NY).

5. Ethical statement

This study was reviewed and approved by the Institutional Review Board of Yonsei Cancer Center (IRB 4-2016-0300). Our institutional review board approved this retrospective study and waived the requirement to obtain informed consent.

Results

1. Baseline characteristics of patients with primary and metastatic uveal melanoma

The baseline characteristics of 226 patients are provided in Table 1. The median age was 53.0 years (range, 18 to 71 years), and 109 patients (48.2%) were male. The most common primary tumor location was the choroid (n=220, 97.3%), and the most common histologic types were epithelioid (n=43, 43.4%) and mixed cell (n=38, 38.4%). The median tumor thickness was 6.2 mm (range, 1.10 to 757.9), and the median LBD was 10.2 mm (range, 1.1 to 30.9). According to the AJCC seventh edition prognostic staging definitions, 26 (25.0%), 66 (63.5%), and 12 (11.5%) patients had stage I, II, and III disease, respectively. An IHC analysis identified 56 BAP1-positive samples (81.2%) among 69 available primary tumor tissues.

Forty-nine patients (21.6%) with primary uveal melanoma developed distant recurrences after local treatment. The baseline characteristics of these patients are also provided in Table 1. The most common location and histologic type of these recurrent uveal melanomas were choroid (n=47, 95.9%) and mixed cell (n=20, 54.1%), respectively. The most common site of distant recurrence was the liver (n=43, 87.7%), followed by the bone (n=11, 22.4%) and lung (n=3, 12.2%).

2. Treatment outcomes for primary and metastatic uveal melanoma

Following a diagnosis of primary uveal melanoma, 160 patients (70.8%) were treated with local radiotherapy, including ¹⁰⁶Ru brachytherapy combined with TTT and gammaknife radiotherapy; 66 patients (29.2%) underwent excision, including primary enucleation, local resection, and TPPV. An analysis of RFS and OS1 according to treatment modality revealed a significantly longer in local radiotherapy than in excision (not reached vs. 82.0 months: 95% confidence intervals [CI], not available [N/A] vs. 43.8-120.2; p < 0.001; not reached vs. 79.5 months: 95% CI, N/A vs. 33.0-126.0; p < 0.001).

Forty-nine patients with distant recurrences of uveal melanoma underwent metastasectomy (n=7, 14.3%), transarterial chemoembolization (TACE) or radiofrequency ablation (RFA) (n=4, 8.2%), local radiotherapy (n=3, 6.1%), or palliative systemic treatments, including chemotherapy and immunotherapy (n=27, 55.1%). Twelve patients who underwent metastasectomy, TACE/RFA, or radiotherapy subsequently received first-line palliative systemic treatment (S1 Fig.). The first-line systemic chemotherapy regimens included dacarbazine (n=27, 77.1%), platinum-based agents (n=7, 20.0%), and topotecan (n=1, 2.9%). The first-line immunotherapies included interferon (n=1, 2.9%) and ipilimumab (n=3, 8.6%). Patients received a mean of 2.94 lines of palliative systemic treatment.

Among patients with distant recurrences of uveal melanoma, the DCR was analyzed according to treatment modality. Here, 71.4% (5/7) of patients with in metastasectomy followed by first-line systemic therapy, 33.3% (9/29) of those receiving only first-line systemic therapy, and 0% of those receiving TACE or RFA or palliative radiotherapy followed by first-line systemic therapy achieved disease control (S2 Table). An analysis of median OS2 duration yielded values of 134.7 (95% CI, 0.0 to 307.6), 8.0 (95% CI, 6.8 to 9.2), 9.2 (95% CI, N/A), 15.7 (95% CI, 13.2 to 18.1), and 7.6 months (95% CI, 0.0 to 25.2) for patients who underwent metastasectomy, TACE or RFA, palliative radiotherapy, only systemic treatments, and observation alone, respectively.

The median OS1 of overall 226 primary uveal melanoma patients was 151.6 months (95% CI, 91.0 to 212.2) and the median OS2 of distant recurrent patients was 15.7 months (95% CI, 13.1 to 18.2).

3. Analysis of prognostic factors

1) BAP1 expression in primary and metastatic uveal melanomas

In accordance with a previous study [8], we subjected 69 primary and 20 metastatic uveal melanoma tissues to BAP1 IHC (Fig. 1A and B). The loss of BAP1 expression was more frequent among metastatic tumor tissues than among primary tissues (13/69 [18.8%] vs. 7/20 [35.0%]) (Table 1). Patients with BAP1-negative primary tumor tissues had a longer median RFS when compared with their BAP1-positive counterparts, although this difference was not statistically significant (not reached vs. 82.0 months, p=0.268) (Fig. 1C). However, patients with BAP1-negative metastatic tumor tissues had a shorter OS2 when compared to those with BAP1-positive tissues; again, this difference was not statistically significant (15.7 months vs. 24.4 months, p=0.216) (Fig. 1D).

2) Prognostic recurrent risk factors analysis of primary uveal melanoma

We next analyzed prognostic factors for the recurrence of primary uveal melanomas following local treatments, as previously mentioned, to enhance risk-based patient stratification. In a univariate analysis, LBD ≥ 15 mm (p < 0.001), depth ≥ 10 mm (p < 0.001), and stage II or III disease (p=0.037 and p=0.013, respectively) were found to have significant adverse effects on relapse (Table 2). A subsequent multivariate analysis included the clinical parameters of age, sex, location, tumor stage and size, and local treatment administration. A forward Cox regression model analysis identified the following significantly poor prognostic factors for relapse (Table 2): tumor basal diameter ≥ 15 mm (hazard ratio [HR], 2.75; 95% CI, 1.09 to 6.90; p=0.032), and depth ≥ 10 mm (HR, 3.07; 95% CI, 1.27 to 7.47; p=0.013).

Next, 226 patients were divided into three subgroups based on multivariate results to identify those who would potentially benefit from primary local treatments: patients without any risk factors and those with 1-2 risk factors (Fig. 2A). Among the 41 patients with one or more risk factors, those who underwent local radiotherapy had a longer median RFS, compared to those who underwent local excision (not reached vs. 19.0 months; 95% CI, N/A vs. 8.40-29.60; p=0.004) (Fig. 2B).

3) Analysis of prognostic and survival risk factors for recurrent uveal melanoma

The univariate analysis identified the recurrence site (liver only, p=0.013), a largest linear metastatic tumor dimension ≥ 45 mm (p=0.025), and RFS < 50 months (p=0.011) as significantly poor prognostic factors for progression despite first-line systemic treatment (Table 3). In a multivariate analysis, the recurrence site (liver only; HR, 6.98; 95% CI, 1.20 to 40.42; p=0.030) and RFS < 50 months (HR, 8.08; 95% CI, 1.82 to 35.84; p=0.006) remained significantly poor prognostic factors for PFS after first-line systemic therapy.

Regarding survival after recurrence, another univariate analysis identified male sex (p=0.004), a largest linear metastatic tumor dimension ≥ 45 mm (p=0.005), and RFS < 50 months (p=0.019) as factors with significant negative adverse effects on OS2 (Table 3). A forward Cox regression model analysis subsequently identified male sex (HR, 3.79; 95% CI, 1.34 to 10.72; p=0.012), a largest linear metastatic tumor dimension ≥ 45 mm (HR, 5.48; 95% CI, 1.36 to 22.18; p=0.017), and short RFS (HR, 4.89; 95% CI, 1.38 to 17.29; p=0.014) as significantly poor prognostic factors for survival after recurrence. Based on the multivariate analysis findings, 49 patientswith distant recurrences of uveal melanoma were divided into four subgroups, and OS2 was found to decrease significantly as the number of risk factors increased (Fig. 3A). Among the 25 patients with two or more risk factors (high-risk group), 19 who received palliative first-line systemic treatment had a significantly longer OS2, compared to those who received supportive care only (13.7 months vs. 4.3 months, p=0.042) (Fig. 3B). Seventeen of 20 patients with one or no risk factors (low-risk group) received first-line systemic therapy and in this group, first-line chemotherapy yielded a longer OS2 relative to immunotherapy (25.3 months vs. 8.0 months, p=0.004) (Fig. 3C).

Discussion

Up to 50% of patients with uveal melanoma will develop metastatic disease after primary local treatment [16]. Such cases are faced with a very poor prognosis and limited therapeutic options with low response rates. Several previous studies have reported the risk factors and characteristics of recurrent uveal melanoma [2-4,10,14,17-19].

In Korean patients, uveal melanomas tend to exhibit vertical growth, with relatively large apical heights and small LBDs [11]. In such cases, the initial radiation doses provided via brachytherapy at the time of diagnosis are insufficient to reach the basal level of the tumor, leading to frequent local and/or distant recurrences and an increased need for enucleation or systemic therapy. Regarding local treatment, our study found that 136 patients (76.8%) in the non-recurrent group received local radiotherapy, while 25 (51.0%) in the recurrent group underwent primary enucleation. Moreover, when compared with non-recurrent tumors, recurrent tumors had a significantly larger primary tumor basal size and significantly more advanced stage. The AJCC Ophthalmic Oncology Group reported that an increasing tumor size was consistent with an increased risk of metastasis [10], and a Taiwanese trial found associations of a larger tumor size and epithelioid or mixed cell type with distant metastasis [17]. Our findings were also supported by prior studies in which patients who underwent with primary enucleation had a higher recurrence rate than did those treated with irradiation [4].

As noted previously, Harbour et al. [7] reported an inactivating somatic mutation in BAP1, located on chromosome 3p21.1, in 47% of all uveal melanomas; 96% of tumors harboring this mutation later metastasized. Koopmans et al. [8] confirmed that this somatic BAP1 mutation correlated strongly with BAP1 expression, and reported an eight-fold increase in the risk of metastasis among patients with BAP1-negative or mutated BAP1-expressing uveal melanoma. In our study, however, we found that BAP1 expression in the primary tumor was associated with a shorter RFS, compared to a loss of BAP1 expression. Our multivariate analysis further identified two risk factors associated with distant recurrence: tumor basal diameter ≥ 15 mm and vertical depth ≥ 10 mm. We further found that in patients with at least one risk factor, local radiotherapy was more effective than local excision or enucleation in terms of RFS prolongation. Accordingly, we recommend that treatment strategies for primary uveal melanoma should be based on these risk factors.

Other investigators have described the patterns of metastatic spread in patients with uveal melanoma [20-23]. Although the liver and lung are the most frequent sites of metastasis, the sites and extent of dissemination vary among studies and reflect differences in study populations, designs, diagnostic tools, and data collection over time. Therefore, the Collaborative Ocular Melanoma Study (COMS) protocol specifies an annual follow-up of patients, including a routine medical examination, liver function studies, and chest X-ray examination [24]. In addition, Hicks et al. [25] recommended routine liver ultrasonography follow-ups after determining the poor sensitivity of a single liver function test for metastatic disease. In our study, the first distant metastatic site in 38 patients (77.6%) was a single organ. Although the liver was the first metastatic site in 81.6% of patients with single-organ involvement and 63.3% of all patients, nearly 40% of all patients presented with non-liver sites of first metastasis (mainly bone). This finding suggests that liver-only screening procedures would miss a substantial proportion of patients. Therefore, guidelines for periodic systemic surveillance should be established for patients in Asia, and particularly those in Korea who have undergone definitive local treatment for primary uveal melanoma.

Although metastatic uveal melanoma is considered a substantial problem, relatively few studies have addressed factors associated with survival. The median survival times of the two largest unselected groups of patients with metastatic uveal melanoma in the COMS and Harvard study were 3.6 and 3.7 months [26,27]. The COMS study reported 1-year and 2-year survival rates of only 19% and 8%, respectively [27]. In our study, we observed a median OS2 of 15.7 months, in contrast to previous studies. We might attribute this discrepancy to the fact that all patients in our study population received local ocular treatment at the time of primary uveal melanoma diagnosis and remained disease-free for a median of 38.1 months. In contrast to previous studies that included only patients initially diagnosed with stage IV disease, we might have observed a lower level of aggressiveness because the recurrences occurred substantially later after local treatment. Additionally, our study included patients who received palliative treatments after metastasectomy from the liver, adrenal gland, or breast mass or after radiotherapy. In a more accurate comparison of patients who underwent metastasectomy with those who received only systemic first-line treatment, the former had a significantly longer survival duration. In addition, patients who received only supportive care had a significantly longer median OS2 duration, compared to those than those who received TACE, RFA, or radiotherapy. Therefore, we would expect the surgical resection of metastatic lesions to yield survival benefits.

In various studies of different groups of patients with metastatic uveal melanoma, the investigators identified multiple predictors of survival duration after the diagnosis of metastasis. The identified poor prognostic factors included patient age, male sex, symptomatic tumor, poor performance status, short metastasis-free interval, anatomic site with metastatic involvement (i.e., hepatic involvement), large number of metastatic sites, and metastatic lesion size [4,28]. In our study, a multivariate analysis identified male sex, a largest linear metastatic tumor diameter ≥ 45 mm, and a short RFS as prognostic factors associated with OS2. As previously observed, high-risk patients (≥ 2 risk factors) who received systemic first-line therapy after distant recurrence had a longer survival duration, compared to those treated with only supportive care. Therefore, high-risk patients should be identified and treated with systemic therapies, as this would be expected to improve survival rates.

Medical oncologists are required to select from among chemotherapy, immunotherapy, or targeted agents when determining the systemic treatment most likely to improve the survival of a patient with metastatic uveal melanoma. However, no effective systemic treatment method has yet been identified, and no reports of non-randomized phase III clinical trials of any alternative or other specific treatments have been published. We note that in our study, the first-line treatments provided for metastatic uveal melanoma varied considerably by subgroup and included surgery, TACE, and/or radiotherapy. The retrospective design of our study limited our analysis of the effect of systemic treatment after relapse. However, given the heterogeneous nature of treatments received by patients in this study, we should be careful when interpreting the efficacies of these first-line systemic treatments. We further note that we have not identified an ideal first-line systemic therapeutic strategy that significantly improved survival, although among patients who received only palliative systemic treatment without surgery, TACE, or radiation for metastatic lesions, those treated with chemotherapy had a significantly longer median OS2, compared to those receiving mmunotherapy (S3 Table). A similar OS2 outcome was also observed among low-risk patients. Among patients receiving only first-line chemotherapy (n=26), a platinum-based regimen was associated with a longer PFS relative to dacarbazine or topotecan. However, dacarbazine seemed to elicit a more durable response and longer OS2 when compared with platinum-based and topotecan, although these differences were not statistically significant (S4 Fig.).

Our study had the following strengths. In our cohort, approximately 40% of patients presented with a non-hepatic first metastasis, which suggests that liver-only screening strategies are likely to fail. Accordingly, bone and chest examinations should also be included in screening protocols, as the early detection of recurrent metastatic lesions will increase the likelihood of surgical resection. Notably, metastasectomy correlated with improved survival in our dataset. Furthermore, relevant studies specific to Asian populations are limited. Our study, which assessed real efficacy in a population of Korean patients, therefore provides important information. Moreover, clinical data were used to score the factors related to overall survival after recurrence and to suggest treatment strategies.

However, this study also had two main limitations. First, we did not conduct gene expression profiling or a full analysis of mutations in genes such as GNAQ, GNA11, or BAP1, which are known poor prognosticators in uveal melanoma. Instead, we confirmed BAP1 expression in primary and metastatic tissues using IHC. Our finding of a high risk of recurrence among patients with BAP1-positive primary tumor tissues contrasted with a previous report [8]. On the other hand, van Essen et al. [29] reported that low RNA levels of BAP1 and negative IHC for BAP1 were predictive of death due to metastasis of uveal melanoma. We also observed an association of the loss of BAP1 expression in metastatic tumors with poor survival in patients with recurrent uveal melanoma patients. These inter-study discrepancies suggest that we should validate our findings using a BAP1 mutation analysis. Second, this study was performed at a single center and featured a retrospective design, and we were unable to compare the effects associated with immunotherapy, chemotherapy, and targeted agent therapy because of the small number of patients with distant recurrences. Therefore, multicenter prospective studies are needed to further estimate the effects of treatment on survival in patients with recurrent uveal melanoma.

In conclusion, the present study conducted a multivariate analysis of clinical and histologic data to identify risk factors related to recurrence in patients with primary uveal melanoma and survival in those with distant recurrent uveal melanoma. Our findings suggest that patients with primary uveal melanoma and one or more risk factors would more strongly benefit from local radiotherapy (vs. local excision or primary enucleation) for recurrence prevention. We also found that for “high risk” patients with recurrent uveal melanoma, more aggressive systemic first-line chemotherapeutic regimens and surgical treatment would likely improve survival. Finally, a multidisciplinary approach combining ophthalmology, radiation oncology, general surgery, and medical oncology should help to improve overall survival in patients with primary and recurrent uveal melanoma

Electronic Supplementary Material

Supplementary materials are available at Cancer Research and Treatment website (http://www.e-crt.org).

crt-2017-534-suppl1.pdf

crt-2017-534-suppl2.pdf

crt-2017-534-suppl3.pdf

crt-2017-534-suppl4.pdf

NOTES

Conflict of interest relevant to this article was not reported.

Acknowledgements

This research was supported by a faculty research grant from the Yonsei University College of Medicine for 2014 (6-2014-0166).

Fig. 1.

Immunohistochemistry (IHC) analysis of primary uveal melanomas without (A) and with BRCA1 associated protein-1 (BAP1) expression (B) (×400). Analysis of recurrence-free survival (RFS, defined as the time from uveal melanoma diagnosis to recurrence) according to BAP1 expression (C). Analysis of overall survival from distant recurrence to death (OS2) according to BAP1 expression in metastatic tissues (D). CI, confidence interval; N/A, not available.

Fig. 2.

Analysis of recurrence-free survival (RFS, defined as the time from choroidal melanoma diagnosis to recurrence) according to risk factors for recurrence of primary uveal melanoma (A). (B) Subgroup analysis according to local treatment with ≥ 1 risk factor. CI, confidence interval; N/A, not available. ^a)Includes tumor basal diameter ≥ 15 mm, depth ≥ 10 mm, ^b)Includes brachytherapy, gamma-knife radiotherapy, transpupillary thermotherapy, ^c)Includes trans pars plana vitrectomy, enucleation, excision, exentration.

Fig. 3.

Analysis of overall survival from distant recurrence to death (OS2) according to survival-related risk factors in patients with metastatic uveal melanoma (A). (B) Subgroup analysis of high-risk patients (≥ 2 risk factors) according to systemic therapy or supportive care. (C) Subgroup analysis of low-risk patients (≤ 1 risk factor) according to the type of systemic treatment. CI, confidence interval. ^a)Includes male sex, largest linear dimension of largest metastatic tumor ≥ 45 mm, recurrence-free survival < 50 months.

Table 1.

Baseline characteristics of primary and metastatic uveal melanoma

Characteristic	Total (n=226)	No recurrence (n=177)	Recurrence (n=49)	p-value^a)
Age, median (range, yr)	53.0 (18-71)	54.0 (18-71)	50.0 (19-61)	0.232
Sex
Male	109 (48.2)	84 (46.2)	28 (53.8)	0.158
Female	117 (51.8)	98 (53.8)	24 (46.2)
Location
Choroid	220 (97.3)	173 (97.7)	47 (95.9)	0.613
Ciliary body	6 (2.7)	4 (2.3)	2 (4.1)
Histology (n=99)
Epithelioid	43 (43.4)	33 (53.2)	10 (27.0)	0.024
Spindle	18 (18.2)	11 (17.7)	7 (18.9)
Mixed	38 (38.4)	18 (29.0)	20 (54.1)
Size, median (range, mm)
Largest basal diameter	10.2 (1.10-30.9)	10.0 (1.1-21.0)	12.0 (4.0-32.0)	0.001
Depth	6.2 (1.10-757.9)	6.0 (1.10-757.0)	7.75 (1.5-18.0)	0.539
Stage (n=104)
I	26 (25.0)	25 (32.5)	1 (3.7)	0.004
II	66 (63.5)	45 (58.4)	21 (77.8)
III	12 (11.5)	7 (9.1)	5 (18.5)
Local treatment
RTx^b)	160 (70.8)	136 (76.8)	24 (49.0)	< 0.001
Excision^c)	66 (29.2)	41 (23.2)	25 (51.0)
Co-morbidity
None	139 (61.5)	107 (60.5)	32 (65.3)	0.772
Cardiovascular disease	7 (3.1)	6 (3.4)	1 (2.0)
HTN	56 (24.8)	45 (25.4)	11 (22.4)
DM	22 (9.7)	18 (10.2)	4 (8.2)
HBV carrier	7 (3.1)	5 (2.8)	2 (4.1)
Others^d)	17 (7.5)	14 (7.9)	3 (6.1)
BAP1 expression (IHC) > 5%
Primary tumor tissue (n=69)
No	13 (18.8)	10 (22.7)	3 (12.0)	0.349
Yes	56 (81.2)	34 (77.3)	22 (88.0)
Metastasis tumor tissue (n=20)
No	-	-	7 (35.0)	0.354
Yes	-	-	13 (65.0)
Recurrence site
Liver	-	-	43 (87.7)	< 0.001
Bone	-	-	11 (22.4)
Lung	-	-	3 (6.1)
Others^e)	-	-	6 (12.2)
First systemic treatment after recurrence
Chemotherapy^f)	-	-	35 (71.4)	-
Immunotherapy^g)	-	-	4 (8.2)
Radiotherapy^h)	-	-	3 (6.1)
TACE, RFA on liver metastasis	-	-	4 (8.2)
Metastatectomyⁱ⁾	-	-	7 (14.3)
Observation	-	-	8 (16.3)
Largest linear dimension of largest metastatic tumor (n=51), median (range, mm)	-	-	25.0 (4-94)	-

Values are presented as number (%) unless otherwise indicated. RTx, radiotherapy; HTN, hypertension; DM, diabetes mellitus; HBV, hepatitis B virus; BAP1, BRCA1-associated protein-1; IHC, immunohistochemistry; TACE, transarterial chemoembolization; RFA, radiofrequency ablation.

^a) Comparison betTeen patients with experience of recurrence or not,

^b) Includes brachytherapy, gamma-knife radiotherapy, and transpupillary thermotherapy,

^c) Includes enucleation, excision, exentration, and trans pars plana vitrectomy,

^d) Includes benign prostate hyperplasia, old TBc, other malignancy, and thyroid disease,

^e) Includes nasal cavity, breast, spleen, brain, and adrenal gland metastasis,

^f) Includes dacarbazine, cisplatin, topotecan, dacarbazine+cisplatin+vincristine, and 5-fluorouracil+carboplatin,

^g) includes ipilimumab and interferon,

^h) Includes radiotherapy to the nasal cavity, spine, adrenal gland, and brain,

ⁱ⁾ Includes splenectomy, liver wedge resection, adrenalectomy, lung lobectomy, skull craniectomy, and maxillectomy.

Table 2.

Univariate and multivariate analyses of risk factors affecting the recurrence of primary uveal melanoma

Characteristic	No.	Median RFS (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis
Characteristic	No.	Median RFS (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age, median (range, yr)
< 30	17	163.0 (N/A)	0.929	1
30-60	141	Not reached		0.83	0.324-2.140	0.703	-	-	-
> 60	68	Not reached		0.85	0.293-2.467	0.765	-	-	-
Sex
Male	109	Not reached	0.062	1.71	0.965-3.043	0.066	-	-	-
Female	117	163.0 (N/A)		1
Location
Choroid	220	163.0 (N/A)	0.452	1
Ciliary body	6	88.0 (N/A)		1.71	0.414-7.048	0.459	-	-	-
Size
Largest basal diameter (mm) (n=223)
< 15	201	163.0 (N/A)	< 0.001	1			1
≥ 15	22	25.0 (0.00-61.18)		4.73	2.326-9.598	< 0.001	2.75	1.092-6.904	0.032
Depth (mm) (n=224)
< 10	193	163.0 (N/A)	< 0.001	1			1
≥ 10	31	54.0 (N/A)		3.37	1.804-6.308	< 0.001	3.07	1.266-7.468	0.013
Stage (n=104)
I	26	Not reached	0.012	1
II	66	82.0 (48.40-115.60)		8.44	1.134-62.787	0.037	-	-	-
III	12	25.0 (N/A)		15.04	1.752-129.043	0.013	-	-	-
Total	226	163.0 (N/A)

RFS, recurrence-free survival (time from the initial diagnosis of uveal melanoma to distant recurrence); CI, confidence interval; HR, hazard ratio; N/A, not available.

Table 3.

Univariate and multivariate analyses of risk factors affecting survival in patients with distant recurrent uveal melanoma

Characteristic	Median first-line PFS									Median OS2
	No.	Median PFS (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis			No.	Median OS2 (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis
	No.	Median PFS (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value	No.	Median OS2 (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age, median (range, yr)
< 30	6	1.57 (1.162-1.978)	0.664	1						6	25.33 (0.000-55.240)	0.173	1
30-60	26	2.03 (1.802-2.258)		1.49	0.511-4.347	0.465	-	-	-	32	15.67 (12.976-18.364)		2.19	0.736-6.530	0.159	-	-	-
> 60	7	2.67 (0.000-5.416)		1.09	0.291-4.099	0.897	-	-	-	11	14.87 (3.667-26.073)		3.27	0.917-11.658	0.068	-	-	-
Sex
Male	21	1.60 (0.957-2.243)	0.241	1.515	0.751-3.058	0.246	-	-	-	28	13.40 (7.869-18.931)	0.002	3.34	1.483-7.537	0.004	3.79	1.341-10.719	0.012
Female	18	2.23 (1.289-3.171)		1						21	24.37 (20.153-28.587)		1			1
Location
Choroid	37	1.97 (1.732-2.208)	0.775	1						47	15.70 (11.170-20.230)	0.690	1
Ciliary body	2	3.83 (N/A)		0.75	0.101-5.534	0.776	-	-	-	2	14.13 (N/A)		1.503	0.200-11.283	0.692	-	-	-
Histology
Epitheloid	9	2.23 (1.850-2.610)	0.755	1						10	15.67 (13.237-18.103)	0.246	1
Spindle	7	2.03 (1.773-2.287)		0.65	0.209-2.027	0.459	-	-	-	7	24.37 (0.000-61.067)		0.41	0.125-1.361	0.146	-	-	-
Mixed	15	2.07 (0.787-3.353)		0.82	0.327-2.047	0.668	-	-	-	20	13.40 (3.829-18.612)		0.98	0.405-2.343	0.954	-	-	-
Size
Largest basal diameter (mm) (n=39)
< 15	31	1.93 (1.534-2.326)	0.106	1						38	15.70 (13.022-18.378)	0.684	1
≥ 15	8	2.83 (1.222-4.438)		0.46	0.176-1.210	0.116	-	-	-	10	14.13 (8.330-31.930)		1.21	0.479-3.073	0.684	-	-	-
Depth (mm) (n=39)
< 10	26	1.87 (1.332-2.408)	0.45	1						34	15.67 (12.605-18.735)	0.725	1
≥ 10	13	2.83 (1.186-4.474)		0.76	0.363-1.574	0.454	-	-	-	14	15.83 (10.330-21.330)		1.14	0.544-2.400	0.725	-	-	-
Recurrence site
Others^a)	6	11.47 (0.000-23.896)	0.024	1			1			6	134.73 (0.000-320.192)	0.108	1
Liver+others^a)	7	2.23 (0.357-4.103)		2.81	0.699-11.299	0.146	8.13	0.945-70.023	0.056	11	10.330 (0.000-24.211)		4.45	0.879-22.527	0.071	-	-	-
Liver only	26	1.93 (1.529-2.331)		4.79	1.388-16.546	0.013	6.98	1.204-40.419	0.030	32	14.87 (11.703-18.037)		4.33	0.986-19.014	0.052	-	-	-
Largest linear dimension of largest metastatic tumor (mm) (n=38)
< 45	32	2.10 (1.074-3.126)	0.017	1						41	17.73 (13.304-22.156)	0.002	1			1
≥ 45	6	1.43 (0.804-2.056)		3.21	1.160-8.877	0.025	-	-	-	7	7.20 (3.932-10.466)		5.19	1.655-16.275	0.005	5.48	1.355-22.181	0.017
RFS (mo)
≥ 50	8	11.47 (3.771-19.169)	0.006	1			1			9	32.93 (0.000-143.300)	0.011	1			1
< 50	31	1.87 (1.477-2.263)		4.06	1.381-11.953	0.011	8.08	1.819-35.842	0.006	40	14.13 (8.117-20.143)		4.30	1.275-14.523	0.019	4.89	1.384-17.291	0.014
Total	39	2.03 (1.789-2.271)								49	15.67 (13.141-18.199)

PFS, progression-free survival (time interval from the initiation of first-line systemic therapies to the date of documented disease progression or death); OS2, overall survival 2 (time from the date of distant recurrence to the date of death from any cause); HR, hazard ratio; CI, confidence interval; RFS, recurrence-free survival.

^a) Includes bone, nasal cavity, breast, lymph node, spleen, brain, and adrenal gland metastasis.

REFERENCES

1. Augsburger JJ, Schneider S, Freire J, Brady LW. Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol. 1999;237:558–67. Article PubMed
2. Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651–9. Article PubMed
3. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118:1881–5. Article PubMed
4. Koutsandrea C, Moschos MM, Dimissianos M, Georgopoulos G, Ladas I, Apostolopoulos M. Metastasis rates and sites after treatment for choroidal melanoma by proton beam irradiation or by enucleation. Clin Ophthalmol. 2008;2:989–95. PubMed PMC
5. Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, et al. Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041). Cancer Chemother Pharmacol. 2017;79:651–60. Article PubMed PMC PDF
6. Kottschade LA, McWilliams RR, Markovic SN, Block MS, Villasboas Bisneto J, Pham AQ, et al. The use of pembrolizumab for the treatment of metastatic uveal melanoma. Melanoma Res. 2016;26:300–3. Article PubMed
7. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science. 2010;330:1410–3. Article PubMed PMC
8. Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol. 2014;27:1321–30. Article PubMed PDF
9. Khattak MA, Fisher R, Hughes P, Gore M, Larkin J. Ipilimumab activity in advanced uveal melanoma. Melanoma Res. 2013;23:79–81. Article PubMed
10. AJCC Ophthalmic Oncology Task Force. International Validation of the American Joint Committee on Cancer's 7th edition classification of uveal melanoma. JAMA Ophthalmol. 2015;133:376–83. Article PubMed
11. Kwon HJ, Ko JS, Kim M, Lee CS, Lee SC. Prognosis of choroidal melanoma and the result of ruthenium brachytherapy combined with transpupillary thermotherapy in Korean patients. Br J Ophthalmol. 2013;97:653–8. Article PubMed
12. Lee JH, Lee SC, Cho A, Keum KC, Suh YG, Lee CS. Association between choroidal thickness and metabolic activity on positron emission tomography in eyes with choroidal melanoma. Am J Ophthalmol. 2015;160:1111–5. Article PubMed
13. Damato BE, Foulds WS. Surgical resection of choroidal melanoma. In: Schachat AP, Ryan SK, editors. Retina. St. Louis, MO: Mosby; 2001. p. 762–72.
14. Foulds WS, Damato BE, Burton RL. Local resection versus enucleation in the management of choroidal melanoma. Eye (Lond). 1987;1(Pt 6):676–9. Article PubMed PDF
15. Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. Br J Ophthalmol. 1998;82:213–8. Article PubMed PMC
16. Buder K, Gesierich A, Gelbrich G, Goebeler M. Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives. Cancer Med. 2013;2:674–86. Article PubMed PMC
17. Liu YC, Tsai CC, Lee FL, Lee SM, Kao SC. Mortality from uveal melanoma treated by enucleation: a 16-year survey in Taiwan. Acta Ophthalmol. 2013;91:e583–4. Article PubMed
18. Murali R, Wiesner T, Scolyer RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116–26. Article PubMed
19. Rietschel P, Panageas KS, Hanlon C, Patel A, Abramson DH, Chapman PB. Variates of survival in metastatic uveal melanoma. J Clin Oncol. 2005;23:8076–80. Article PubMed
20. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670–6. Article PubMed
21. Kath R, Hayungs J, Bornfeld N, Sauerwein W, Hoffken K, Seeber S. Prognosis and treatment of disseminated uveal melanoma. Cancer. 1993;72:2219–23. Article PubMed
22. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665–70. Article PubMed
23. Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer. 1998;34 Suppl 3:S27–30. Article PubMed
24. Collaborative Ocular Melanoma Study Group. COMS Manual of Procedures (1999). NTIS accession No. PB95-179693. Springfield: National Technical Information Service; 1999.
25. Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye (Lond). 1998;12(Pt 6):945–8. Article PubMed PDF
26. Gragoudas ES, Egan KM, Seddon JM, Glynn RJ, Walsh SM, Finn SM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383–9. Article PubMed
27. Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438–44. Article PubMed
28. Augsburger JJ, Correa ZM, Shaikh AH. Effectiveness of treatments for metastatic uveal melanoma. Am J Ophthalmol. 2009;148:119–27. Article PubMed
29. van Essen TH, van Pelt SI, Versluis M, Bronkhorst IH, van Duinen SG, Marinkovic M, et al. Prognostic parameters in uveal melanoma and their association with BAP1 expression. Br J Ophthalmol. 2014;98:1738–43. Article PubMed PMC

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery
Louis Cappelli, Mehak M. Khan, Carol L. Shields, Sara E. Lally, Muhammad Sharif, Haisong Liu, Yingxuan Chen, Jade Park, Tingting Zhan, Wenyin Shi
American Journal of Ophthalmology.2025; 271: 417. CrossRef
Genetic landscape of uveal melanoma in Southeast Asia: high 1q gains and unique patterns of metastasis risk
Chuanfei Chen, Mona Meng Wang, Alvin Soon Tiong Lim, Evelyn Yee Hsieh Heng, Sim Leng Tien, Sunny Yu Shen, Gavin Siew Wei Tan, Jason Yongsheng Chan, Anita Sook Yee Chan
Eye and Vision.2025;[Epub] CrossRef
Nanocomposite from Alpha-Tocopheryl Succinate and Chitosan-modified-graphene for Efficient Inhibition on Choroidal Melanoma via a Chemotherapy-assisted-photothermal Therapy
Feng Yuan, Dan Lin, Yue Zhang, Kang Han, Qing Xu, He Ma, Ping-Ping Huang, Yong Liu, Ling-Dan Kong
Chinese Journal of Polymer Science.2025; 43(8): 1387. CrossRef
Features of uveal melanoma clinical course
A. R. Osokin, M. A. Engibaryan, A. A. Shulga, A. P. Menshenina, I. V. Golovinov, D. V. Khodakova, A. V. Galina, S. V. Gurova, L. N. Vashchenko, A. V. Snezhko
Research and Practical Medicine Journal.2025; 12(3): 42. CrossRef
Decoding the ubiquitin network: molecular mechanisms and therapeutic vulnerabilities for precision radio-sensitization in cancer
Fu-Ying Zhao, Li-Ye Shi, Lu-Jiao Yu, Si-Qi Wang, Chu-Yao Sun, Na Zhang, Hua-Qin Wang
Molecular Cancer.2025;[Epub] CrossRef
Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives
Merve Kulbay, Emily Marcotte, Raheem Remtulla, Tsz Hin Alexander Lau, Manuel Paez-Escamilla, Kevin Y. Wu, Miguel N. Burnier
Biomedicines.2024; 12(8): 1758. CrossRef
Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study
Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard
Cancers.2024; 16(19): 3346. CrossRef
Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma
Binghua Yang, Yuxia Fan, Renlong Liang, Yi Wu, Aiping Gu
BMC Ophthalmology.2023;[Epub] CrossRef
Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result
Yaping Su, Xiaolin Xu, Fang Wang, Panli Zuo, Qinghua Chen, Wenbin Wei, Junfang Xian
Journal of Computer Assisted Tomography.2023; 47(1): 151. CrossRef
Uveal melanoma pathobiology: Metastasis to the liver
Prisca Bustamante, Léo Piquet, Solange Landreville, Julia V. Burnier
Seminars in Cancer Biology.2021; 71: 65. CrossRef
Malignant uveal melanoma with metastatic recurrence to the pancreas: A case report
Wei‐Chun Weng, Tzung‐Jiun Tsai, Wen‐Chi Chen, Jin‐Shiung Cheng, Wei‐Chih Sun
Advances in Digestive Medicine.2021; 8(3): 178. CrossRef
Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort
Paula Silva‐Rodríguez, Manuel Bande, Daniel Fernández‐Díaz, Nerea Lago‐Baameiro, María Pardo, María José Blanco‐Teijeiro, Fernando Domínguez, Lourdes Loidi, Antonio Piñeiro
Acta Ophthalmologica.2021;[Epub] CrossRef
Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort
Laura Ling Ying Tan, Jiancheng Hong, Wei Lin Goh, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Anita Sook Yee Chan, Jason Yongsheng Chan
Scientific Reports.2020;[Epub] CrossRef
ЕФЕКТИВНІСТЬ РАДІОХВИЛЬОВОЇ (3,8 МГЦ) БЛОКЕКСЦИЗІЇ МЕЛАНОМИ ЦИЛІОХОРІОЇДАЛЬНОЇ ЛОКАЛІЗАЦІЇ
O. V. Khomyakova
Здобутки клінічної і експериментальної медицини.2020; (3): 173. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

Cancer Res Treat. 2018;50(4):1238-1251. Published online December 28, 2017

DOI: https://doi.org/10.4143/crt.2017.534

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Electronic Supplementary Material
NOTES
REFERENCES

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

Fig. 1. Immunohistochemistry (IHC) analysis of primary uveal melanomas without (A) and with BRCA1 associated protein-1 (BAP1) expression (B) (×400). Analysis of recurrence-free survival (RFS, defined as the time from uveal melanoma diagnosis to recurrence) according to BAP1 expression (C). Analysis of overall survival from distant recurrence to death (OS2) according to BAP1 expression in metastatic tissues (D). CI, confidence interval; N/A, not available.

Fig. 2. Analysis of recurrence-free survival (RFS, defined as the time from choroidal melanoma diagnosis to recurrence) according to risk factors for recurrence of primary uveal melanoma (A). (B) Subgroup analysis according to local treatment with ≥ 1 risk factor. CI, confidence interval; N/A, not available. a)Includes tumor basal diameter ≥ 15 mm, depth ≥ 10 mm, b)Includes brachytherapy, gamma-knife radiotherapy, transpupillary thermotherapy, c)Includes trans pars plana vitrectomy, enucleation, excision, exentration.

Fig. 3. Analysis of overall survival from distant recurrence to death (OS2) according to survival-related risk factors in patients with metastatic uveal melanoma (A). (B) Subgroup analysis of high-risk patients (≥ 2 risk factors) according to systemic therapy or supportive care. (C) Subgroup analysis of low-risk patients (≤ 1 risk factor) according to the type of systemic treatment. CI, confidence interval. a)Includes male sex, largest linear dimension of largest metastatic tumor ≥ 45 mm, recurrence-free survival < 50 months.

Fig. 1.

Fig. 2.

Fig. 3.

Prognoses and Clinical Outcomes of Primary and Recurrent Uveal Melanoma

Characteristic	Total (n=226)	No recurrence (n=177)	Recurrence (n=49)	p-value^a)
Age, median (range, yr)	53.0 (18-71)	54.0 (18-71)	50.0 (19-61)	0.232
Sex
Male	109 (48.2)	84 (46.2)	28 (53.8)	0.158
Female	117 (51.8)	98 (53.8)	24 (46.2)
Location
Choroid	220 (97.3)	173 (97.7)	47 (95.9)	0.613
Ciliary body	6 (2.7)	4 (2.3)	2 (4.1)
Histology (n=99)
Epithelioid	43 (43.4)	33 (53.2)	10 (27.0)	0.024
Spindle	18 (18.2)	11 (17.7)	7 (18.9)
Mixed	38 (38.4)	18 (29.0)	20 (54.1)
Size, median (range, mm)
Largest basal diameter	10.2 (1.10-30.9)	10.0 (1.1-21.0)	12.0 (4.0-32.0)	0.001
Depth	6.2 (1.10-757.9)	6.0 (1.10-757.0)	7.75 (1.5-18.0)	0.539
Stage (n=104)
I	26 (25.0)	25 (32.5)	1 (3.7)	0.004
II	66 (63.5)	45 (58.4)	21 (77.8)
III	12 (11.5)	7 (9.1)	5 (18.5)
Local treatment
RTx^b)	160 (70.8)	136 (76.8)	24 (49.0)	< 0.001
Excision^c)	66 (29.2)	41 (23.2)	25 (51.0)
Co-morbidity
None	139 (61.5)	107 (60.5)	32 (65.3)	0.772
Cardiovascular disease	7 (3.1)	6 (3.4)	1 (2.0)
HTN	56 (24.8)	45 (25.4)	11 (22.4)
DM	22 (9.7)	18 (10.2)	4 (8.2)
HBV carrier	7 (3.1)	5 (2.8)	2 (4.1)
Others^d)	17 (7.5)	14 (7.9)	3 (6.1)
BAP1 expression (IHC) > 5%
Primary tumor tissue (n=69)
No	13 (18.8)	10 (22.7)	3 (12.0)	0.349
Yes	56 (81.2)	34 (77.3)	22 (88.0)
Metastasis tumor tissue (n=20)
No	-	-	7 (35.0)	0.354
Yes	-	-	13 (65.0)
Recurrence site
Liver	-	-	43 (87.7)	< 0.001
Bone	-	-	11 (22.4)
Lung	-	-	3 (6.1)
Others^e)	-	-	6 (12.2)
First systemic treatment after recurrence
Chemotherapy^f)	-	-	35 (71.4)	-
Immunotherapy^g)	-	-	4 (8.2)
Radiotherapy^h)	-	-	3 (6.1)
TACE, RFA on liver metastasis	-	-	4 (8.2)
Metastatectomyⁱ⁾	-	-	7 (14.3)
Observation	-	-	8 (16.3)
Largest linear dimension of largest metastatic tumor (n=51), median (range, mm)	-	-	25.0 (4-94)	-

Characteristic	No.	Median RFS (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis
Characteristic	No.	Median RFS (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age, median (range, yr)
< 30	17	163.0 (N/A)	0.929	1
30-60	141	Not reached		0.83	0.324-2.140	0.703	-	-	-
> 60	68	Not reached		0.85	0.293-2.467	0.765	-	-	-
Sex
Male	109	Not reached	0.062	1.71	0.965-3.043	0.066	-	-	-
Female	117	163.0 (N/A)		1
Location
Choroid	220	163.0 (N/A)	0.452	1
Ciliary body	6	88.0 (N/A)		1.71	0.414-7.048	0.459	-	-	-
Size
Largest basal diameter (mm) (n=223)
< 15	201	163.0 (N/A)	< 0.001	1			1
≥ 15	22	25.0 (0.00-61.18)		4.73	2.326-9.598	< 0.001	2.75	1.092-6.904	0.032
Depth (mm) (n=224)
< 10	193	163.0 (N/A)	< 0.001	1			1
≥ 10	31	54.0 (N/A)		3.37	1.804-6.308	< 0.001	3.07	1.266-7.468	0.013
Stage (n=104)
I	26	Not reached	0.012	1
II	66	82.0 (48.40-115.60)		8.44	1.134-62.787	0.037	-	-	-
III	12	25.0 (N/A)		15.04	1.752-129.043	0.013	-	-	-
Total	226	163.0 (N/A)

Characteristic	Median first-line PFS									Median OS2
	No.	Median PFS (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis			No.	Median OS2 (95% CI, mo)	p-value	Univariate analysis			Multivariate analysis
	No.	Median PFS (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value	No.	Median OS2 (95% CI, mo)	p-value	HR	95% CI	p-value	HR	95% CI	p-value
Age, median (range, yr)
< 30	6	1.57 (1.162-1.978)	0.664	1						6	25.33 (0.000-55.240)	0.173	1
30-60	26	2.03 (1.802-2.258)		1.49	0.511-4.347	0.465	-	-	-	32	15.67 (12.976-18.364)		2.19	0.736-6.530	0.159	-	-	-
> 60	7	2.67 (0.000-5.416)		1.09	0.291-4.099	0.897	-	-	-	11	14.87 (3.667-26.073)		3.27	0.917-11.658	0.068	-	-	-
Sex
Male	21	1.60 (0.957-2.243)	0.241	1.515	0.751-3.058	0.246	-	-	-	28	13.40 (7.869-18.931)	0.002	3.34	1.483-7.537	0.004	3.79	1.341-10.719	0.012
Female	18	2.23 (1.289-3.171)		1						21	24.37 (20.153-28.587)		1			1
Location
Choroid	37	1.97 (1.732-2.208)	0.775	1						47	15.70 (11.170-20.230)	0.690	1
Ciliary body	2	3.83 (N/A)		0.75	0.101-5.534	0.776	-	-	-	2	14.13 (N/A)		1.503	0.200-11.283	0.692	-	-	-
Histology
Epitheloid	9	2.23 (1.850-2.610)	0.755	1						10	15.67 (13.237-18.103)	0.246	1
Spindle	7	2.03 (1.773-2.287)		0.65	0.209-2.027	0.459	-	-	-	7	24.37 (0.000-61.067)		0.41	0.125-1.361	0.146	-	-	-
Mixed	15	2.07 (0.787-3.353)		0.82	0.327-2.047	0.668	-	-	-	20	13.40 (3.829-18.612)		0.98	0.405-2.343	0.954	-	-	-
Size
Largest basal diameter (mm) (n=39)
< 15	31	1.93 (1.534-2.326)	0.106	1						38	15.70 (13.022-18.378)	0.684	1
≥ 15	8	2.83 (1.222-4.438)		0.46	0.176-1.210	0.116	-	-	-	10	14.13 (8.330-31.930)		1.21	0.479-3.073	0.684	-	-	-
Depth (mm) (n=39)
< 10	26	1.87 (1.332-2.408)	0.45	1						34	15.67 (12.605-18.735)	0.725	1
≥ 10	13	2.83 (1.186-4.474)		0.76	0.363-1.574	0.454	-	-	-	14	15.83 (10.330-21.330)		1.14	0.544-2.400	0.725	-	-	-
Recurrence site
Others^a)	6	11.47 (0.000-23.896)	0.024	1			1			6	134.73 (0.000-320.192)	0.108	1
Liver+others^a)	7	2.23 (0.357-4.103)		2.81	0.699-11.299	0.146	8.13	0.945-70.023	0.056	11	10.330 (0.000-24.211)		4.45	0.879-22.527	0.071	-	-	-
Liver only	26	1.93 (1.529-2.331)		4.79	1.388-16.546	0.013	6.98	1.204-40.419	0.030	32	14.87 (11.703-18.037)		4.33	0.986-19.014	0.052	-	-	-
Largest linear dimension of largest metastatic tumor (mm) (n=38)
< 45	32	2.10 (1.074-3.126)	0.017	1						41	17.73 (13.304-22.156)	0.002	1			1
≥ 45	6	1.43 (0.804-2.056)		3.21	1.160-8.877	0.025	-	-	-	7	7.20 (3.932-10.466)		5.19	1.655-16.275	0.005	5.48	1.355-22.181	0.017
RFS (mo)
≥ 50	8	11.47 (3.771-19.169)	0.006	1			1			9	32.93 (0.000-143.300)	0.011	1			1
< 50	31	1.87 (1.477-2.263)		4.06	1.381-11.953	0.011	8.08	1.819-35.842	0.006	40	14.13 (8.117-20.143)		4.30	1.275-14.523	0.019	4.89	1.384-17.291	0.014
Total	39	2.03 (1.789-2.271)								49	15.67 (13.141-18.199)

Table 1. Baseline characteristics of primary and metastatic uveal melanoma

Comparison betTeen patients with experience of recurrence or not,

Includes brachytherapy, gamma-knife radiotherapy, and transpupillary thermotherapy,

Includes enucleation, excision, exentration, and trans pars plana vitrectomy,

Includes benign prostate hyperplasia, old TBc, other malignancy, and thyroid disease,

Includes nasal cavity, breast, spleen, brain, and adrenal gland metastasis,

Includes dacarbazine, cisplatin, topotecan, dacarbazine+cisplatin+vincristine, and 5-fluorouracil+carboplatin,

includes ipilimumab and interferon,

Includes radiotherapy to the nasal cavity, spine, adrenal gland, and brain,

Includes splenectomy, liver wedge resection, adrenalectomy, lung lobectomy, skull craniectomy, and maxillectomy.

Table 2. Univariate and multivariate analyses of risk factors affecting the recurrence of primary uveal melanoma

RFS, recurrence-free survival (time from the initial diagnosis of uveal melanoma to distant recurrence); CI, confidence interval; HR, hazard ratio; N/A, not available.

Table 3. Univariate and multivariate analyses of risk factors affecting survival in patients with distant recurrent uveal melanoma

Includes bone, nasal cavity, breast, lymph node, spleen, brain, and adrenal gland metastasis.